Login

Categories

Consumer Corporate Energy Entertainment Experts Financials Healthcare Industrial Law Markets Media Mining Private Equity Real Estates Sports Startups Technology Venture Capital

Recent Videos

00:00:00
aims to be an innovative drug discovery and development company - Michael A. Martino, Chief Executive Officer, Ampio Pharmaceuticals Inc
00:00:00
Michael A. Martino, Chief Executive Officer, Ampio Pharmaceuticals Inc
00:00:00
Paul Grint Discusses AmpliPhi Biosciences - Paul Grint, CEO, AmpliPhi Biosciences Corp
00:00:00
Amryt Pharma hail rocketing revenue growth 'we're a biotech that makes money - Joe Wiley, CEO, Amryt Pharma
00:00:00
Anatara Lifesciences with Proactive at ASX Small and Mid-Cap Conference - Steve Lydeamore, CEO, Anatara Lifesciences Ltd
00:00:00
Anatara Lifesciences transitions gut health focus from animals to humans - Steve Lydeamore, CEO, Anatara Lifesciences Ltd
00:00:00
Christopher U. Missling Ph.D. , CEO, Anavex Life Sciences Corp
00:00:00
Anders Hultman, CEO, AroCell AB (publ)
00:00:00
Avacta Group boss explains potential of its Affimer technology - Alastair Smith, CEO, Avacta Group Chief Executive Officer
00:00:00
Avita Medical CEO: Burn Care Advancements | Dr. Michael Perry, CEO, Avita Medical Ltd
00:00:00
BBS's company presentation , Ilkka Kangasniemi, CEO, BBS-Bioactive Bone Substitutes
00:00:00
Darren Stralow Managing Director and CEO, Bellevue Gold Ltd
00:00:00
Carl Syubbings, CEO, Benitec Biopharma Ltd
00:00:00
BerGenBio (BGBIO) is a clinical-stage biopharmaceutical company - Martin Olin , Chief Executive Officer, Bergenbio
00:00:00
Bio-Works CEO, Jonathan Royce, interview - Jonathan Royce Chief Executive Officer, Bio-Works Technologies
00:00:00
Bioasis Technologies forms 'exciting' licensing agreement with Chiesi Global Rare Diseases - Deborah Rathjen, B.Sc. (Hons), Ph.D., MAICD, FTSE -Executive Chair, biOasis Technologies Inc
00:00:00
BioInvents's CEO Martin Welschof presents the company - Martin Welschof Chief Executive Officer, BioInvent International
00:00:00
Biophytis sees positive data from PHASE 2-3 COVA CLINICAL STUDY of Sarconeos - Stanislas Veillet , CEO, Biophytis
00:00:00
BioPorto discusses 'fantastic first half of the year' driven by antibodies and RUO NGAL Test sales - Peter Mørch Eriksen, CEO/Board Member,Bioporto
00:00:00
BioPorto CEO explains why he's expecting 2021 to be a 'pivotal year - Peter Mørch Eriksen, CEO/Board Member,Bioporto

© 2017 - Neuhu+